Wegovy has become a popular choice for weight loss, helping many shed significant pounds. Its success has sparked interest in newer medications that might work even better. People want to know what new weight loss drug is better than Wegovy.
Recent advancements have introduced drugs like Zepbound and experimental options like amycretin. These medications promise greater weight loss or fewer side effects. This article explores how they compare to Wegovy in simple terms.
With clear explanations and the latest insights, we’ll guide you through these options. From how they work to their effectiveness, you’ll learn what might suit your needs. Let’s dive into the world of weight loss treatments.
Understanding Wegovy and Its Role
Wegovy is a weekly injection containing semaglutide, a GLP-1 receptor agonist. It mimics a hormone that controls appetite, helping you feel full longer. This reduces cravings and supports weight loss.
Approved by the FDA in 2021, Wegovy is for adults with obesity or overweight with conditions like diabetes. It typically leads to 15% body weight loss over 68 weeks. It’s effective when paired with diet and exercise.
Wegovy’s success has set a high standard. However, newer drugs are emerging with bold claims. Let’s explore what new weight loss drug is better than Wegovy.
Zepbound: A Strong Contender
Zepbound, approved by the FDA in 2023, contains tirzepatide. Unlike Wegovy, it targets both GLP-1 and GIP hormones. This dual action boosts appetite suppression and fat metabolism.
Clinical trials show Zepbound outperforms Wegovy. In the SURMOUNT-1 trial, users lost up to 22.5% of body weight in 72 weeks. This is notably higher than Wegovy’s 15%.
Zepbound is injected weekly, like Wegovy, with doses of 5, 10, or 15 mg. Its higher doses often lead to greater weight loss. It’s also being studied for benefits like sleep apnea treatment.
Amycretin: The Next Big Thing?
Amycretin is an experimental oral weight loss drug from Novo Nordisk, Wegovy’s maker. It targets GLP-1 and amylin hormones, offering a pill instead of an injection. This could appeal to those who dislike needles.
Early trials show amycretin may lead to faster weight loss. In a Phase 1 trial, users lost up to 13% of body weight in 12 weeks. This surpasses Wegovy’s 6% at the same stage.
Amycretin is still in development, with results expected in 2025. It’s not yet FDA-approved, but its potential is exciting. More research is needed to confirm its edge over Wegovy.
How These Drugs Compare
Zepbound and Wegovy both rely on GLP-1 to reduce appetite. Zepbound’s added GIP action may enhance fat breakdown, leading to more weight loss. Amycretin’s amylin targeting could offer faster results.
In a head-to-head trial, Zepbound users lost 20.2% of body weight in 72 weeks, compared to Wegovy’s 13.7%. This makes Zepbound a strong answer to what new weight loss drug is better than Wegovy. Amycretin’s data is less complete but promising.
Side effects are similar across these drugs, including nausea and diarrhea. Zepbound may cause less vomiting, possibly due to GIP’s role in reducing nausea. Amycretin’s side effect profile aligns with Wegovy’s.
Weight Loss Comparison Table
| Drug | Active Ingredient | Average Weight Loss | Time Frame | Administration |
|---|---|---|---|---|
| Wegovy | Semaglutide | 15% | 68 weeks | Weekly injection |
| Zepbound | Tirzepatide | 20.2% | 72 weeks | Weekly injection |
| Amycretin | Amycretin | 13% | 12 weeks | Daily pill (experimental) |
This table highlights key differences in effectiveness and delivery. Zepbound leads in weight loss, while amycretin offers a non-injectable option.
Factors to Consider When Choosing
Effectiveness isn’t the only factor in picking a weight loss drug. Your health goals, like managing heart disease or sleep apnea, matter. Wegovy is approved for cardiovascular risk reduction, unlike Zepbound.
Cost is a major concern. Both Wegovy and Zepbound cost over $1,000 monthly without insurance. Amycretin’s price is unknown, but pills may be cheaper to produce.
Your tolerance for side effects also plays a role. Some handle Zepbound better, while others prefer Wegovy. Consult your doctor to match the drug to your needs.
Side Effects and Safety
Wegovy, Zepbound, and amycretin share common side effects like nausea, vomiting, and diarrhea. These often fade as your body adjusts. Starting with low doses helps minimize discomfort.
Zepbound may cause less vomiting, which could be a plus for some. Serious risks, like pancreatitis or thyroid issues, are rare but require monitoring. Always report unusual symptoms to your doctor.
Amycretin’s safety profile is still under study. Early data suggests it’s similar to Wegovy. Long-term risks for all these drugs are still being researched.
Tips for Managing Side Effects
- Start with the lowest dose to ease your body into treatment.
- Stay hydrated to reduce nausea and prevent dehydration.
- Eat smaller, frequent meals to avoid stomach upset.
- Discuss persistent side effects with your doctor promptly.
Lifestyle Changes for Best Results
No drug works alone. Pairing Wegovy, Zepbound, or amycretin with a healthy diet boosts results. Focus on vegetables, lean proteins, and whole grains for balanced nutrition.
Exercise is crucial. Aim for 150 minutes of moderate activity weekly, like brisk walking. This supports weight loss and overall health.
Consistency matters. Sticking to your medication schedule and lifestyle changes ensures lasting results. Work with your doctor to create a sustainable plan.
Who Should Consider These Drugs?
Wegovy and Zepbound are for adults with a BMI of 30 or higher, or 27 with conditions like high blood pressure. Wegovy is also approved for teens aged 12 and older. Amycretin’s eligibility is unclear until approved.
Those with a history of thyroid cancer or certain endocrine conditions should avoid these drugs. Your doctor will review your medical history to ensure safety.
These medications aren’t for cosmetic weight loss. They’re designed for those with obesity or related health issues. Commitment to lifestyle changes is essential.
Cost and Accessibility Challenges
Wegovy and Zepbound are expensive, often over $1,000 monthly without coverage. Insurance rarely covers them for weight loss alone. This limits access for many.
Amycretin, as a pill, may eventually be more affordable. However, its cost is unknown until it’s market-ready. Check with your insurance for coverage options.
Some pharmacies offer savings programs for Wegovy and Zepbound. Your doctor or pharmacist can guide you to these resources.
What If You Stop Taking the Drug?
Stopping Wegovy or Zepbound often leads to weight regain. Studies show users regain about 70% of lost weight within a year of stopping. Long-term use is typically needed.
Amycretin’s effects after stopping are less studied. Its early data suggests similar challenges. Maintaining diet and exercise helps prevent regain.
Your doctor may suggest a lower maintenance dose. This can help sustain results while reducing costs or side effects.
Future of Weight Loss Drugs
The weight loss drug market is evolving fast. Zepbound’s success shows dual-hormone drugs may outperform single-hormone ones like Wegovy. Amycretin’s oral form could change the game.
More drugs are in development. Companies like Pfizer are exploring new options. Increased competition may lower costs and improve access over time.
Research continues on health benefits beyond weight loss. Zepbound and Wegovy show promise for heart health and sleep apnea. Future studies will clarify their full potential.
Summary
When exploring what new weight loss drug is better than Wegovy, Zepbound stands out with its 20.2% average weight loss compared to Wegovy’s 13.7% in head-to-head trials. Its dual GLP-1 and GIP action drives stronger results. Amycretin, an experimental pill, shows early promise with 13% weight loss in 12 weeks, but it’s not yet approved. Both drugs share similar side effects, though Zepbound may cause less vomiting. Cost, accessibility, and health goals influence the best choice. Combining any drug with diet and exercise is key for lasting success.
FAQ
What new weight loss drug is better than Wegovy?
Zepbound (tirzepatide) outperforms Wegovy in trials, with 20.2% weight loss versus 13.7% over 72 weeks. Amycretin, an experimental pill, shows promise but isn’t approved yet. Consult your doctor for the best option.
How does Zepbound differ from Wegovy?
Zepbound targets both GLP-1 and GIP hormones, enhancing weight loss and fat metabolism. Wegovy focuses only on GLP-1. This dual action makes Zepbound more effective for many.
Is amycretin available now?
Amycretin is in clinical trials and not yet FDA-approved. Early data shows up to 13% weight loss in 12 weeks. Results from ongoing studies are expected in 2025.
Are side effects worse with newer drugs?
Zepbound and Wegovy have similar side effects, like nausea and diarrhea. Zepbound may cause less vomiting. Amycretin’s side effects are comparable but need more study.
Can I switch from Wegovy to Zepbound?
Yes, but your doctor will start you on a low Zepbound dose to adjust. Switching may help if Wegovy isn’t effective enough. Discuss your health goals with your doctor.
Dr. Hamza is a medical content reviewer with over 12+ years of experience in healthcare research and patient education. He specializes in evidence-based health information, medications, and chronic conditions. His reviews are grounded in trusted medical sources and current clinical guidelines to ensure accuracy, transparency, and reliability. Content reviewed by Dr. Hamza is intended for educational purposes and is not a substitute for professional medical advice.